# Abstract

**Background & Aims:** The incidence of locally acquired hepatitis E increased in recent years across Europe. There are only a few data on hepatitis E in Romania. The purpose of our research was to describe and compare hepatitis E and hepatitis A in adult patients.

**Methods:** We included all consecutive adult patients with hepatitis E (48) and hepatitis A (152) admitted in the Teaching Hospital of Infectious Diseases, Cluj-Napoca, Romania between January 2017 and August 2019.

**Results:** Hepatitis E incidence increased in 2018-2019 compared to 2017. The average age in hepatitis E patients was 50.6, while ~~the maximum incidence of hepatitis A in Romania was found in children.~~ Two-thirds of the patients in both groups were men. Compared to hepatitis A, patients with hepatitis E presented a milder course of disease with significantly less modified AST and ALT, bilirubin, prothrombin index and INR levels. We found a higher prevalence of comorbidities in hepatitis E patients adjusted for age & gender. Severe forms were found in 5 (3.3%) hepatitis A patients compared to 12 (25%) of hepatitis E patients, of which 3 died. Acute-on-chronic hepatitis E and immunosuppression were found in 6 and 5 patients, respectively.

**Conclusions:** Our study shows that hepatitis E incidence is increasing, being usually self-limited and milder compared to hepatitis A. Ribavirin treatment seems to be beneficial in patients with preexisting conditions.

# Keywords

hepatitis e, hepatitis a, ribavirin

# Background & Aims

Hepatitis E is an anthropozoonosis with typically mild evolution caused by the Hepatitis E virus (HEV), the *Hepeviridae* family, whose members infect humans and other mammals [1, 2]. Genotypes 3 and 4 are the most common in Europe, where the reservoir of infection is represented by asymptomatic but highly infectious pigs and wild boars (with reproductive rate up to 8) [3–6]. Transmission occurs through consumption of contaminated and undercooked pork or other meat products [7, 8] but other transmission routes have also been demonstrated (shellfish [9], blood transfusions [10, 11], contact with contaminated water or infected animals [12]). Vegetable products are rarely associated with HEV in Europe, probably due to tight regulation of pig manure use in farming [7, 13]. These genotypes may lead to chronic disease in immunocompromised patients [5, 14]. Yet, the majority of individuals are asymptomatic [15].

Genotypes 1 and 2 of HEV are obligate human pathogens that only cause acute disease and are more common in developing countries: Asia (genotype 1), Africa (genotype 2) and Central America (both), being transmitted through fecal-oral route and contaminated water [5].

The number of laboratory-confirmed cases increased across Europe since 2006 to even more cases than hepatitis A in Germany, UK and France [3] with an estimated two million locally acquired cases each year in Europe [5].

HEV infects the liver but may be present in other organs (brain, kidney, placenta) [16, 17] and RNA becomes detectable in blood and feces after 2-3 weeks post-exposure and lasting 3-6 weeks. After an incubation of 15-60 days, liver enzymes, IgM and then IgG levels increase, marking the clinical onset. IgM may persist up to 1 year, IgG are long-lasting and, in immunosuppressed patients, RNA may be detectable for more than 6 months, considered chronic infection [5].

Risk factors for clinical manifestations include male gender, age over 50 and preexisting liver disease [7, 18]. Acute-on-chronic liver failure has considerable fatality but benefits from antiviral treatment (ribavirin, interferon) [19, 20]. Occasionally, neurologic lesions in acute hepatitis E patients were reported and include neuralgic amyotrophy, Bell palsy, Guillain-Barré syndrome, encephalitis and myelitis [21, 22]. Chronic cases (HEV clearance failure after 6 months) have been reported in solid organ transplant recipients presenting long-lasting fatigue, elevated AST, ALT and γ-GT and sometimes negative anti-HEV IgM and IgG [14, 23, 24]. EASL recommends HEV testing in patients with the aforementioned pathologies, regardless of liver enzyme levels [5].

According to Romanian regulations, all confirmed and suspected cases of acute viral hepatitis (A to E) should be admitted and treated in an appropriate hospital.

Our objective was to describe all cases of HEV infection admitted in our hospital during the study period (January 2017 - August 2019) in comparison to all hepatitis A adult patients. We focused on patient characteristics that were available from our hospital’s electronic records.

# Methods

We performed a retrospective case-control study including all consecutive adult (>18 years old) hepatitis E and A cases registered in our hospital’s (The Teaching Hospital of Infectious Diseases of Cluj-Napoca, Romania) electronic database starting from 2017 January 1 until 2019 August 30. Our institution serves the Transylvania region, but most patients live in Cluj County. All clinical departments within our hospital were considered similar regarding diagnosis and management of patients.

Hepatitis A and E were diagnosed by qualitative anti-HAV and anti-HEV IgM respectively using *bioMérieux VIDAS® Hepatitis panel* electrochemiluminescence immunoassays from blood samples [25].

All patients received appropriate supportive treatment according to our hospital protocols and general recommendations. We defined a severe case of hepatitis E if INR >1.5, hepatic encephalopathy grades 2-4 and/or comorbidities (acute-on-chronic liver disease, confirmed immunosuppression) or neurological manifestations were found (according to EASL guideline 2018) [5]. The therapeutic approach for these patients was supportive treatment *plus* ribavirin (600-800 mg/day). We defined severe cases of hepatitis A if INR >1.5, hepatic encephalopathy grades 2-4 were present. The therapeutic approach for these patients was supportive treatment *plus* plasma products.

All patient data were collected from electronic records. These include laboratory parameters at admission, final diagnosis according to ICM10 codes and doctors’ description of each patient’s presentation and evolution. For subjective parameters, the judgment of all doctors assigned to each patient was considered equivalent.

All patients signed an informed consent form. This study was approved by the ethics committee of our institution.

Data were centralized in a spreadsheet, checked for consistency, anonymized and imported into R 3.6.1[[1]](#footnote-1) on Linux where all subsequent statistical analyses were performed. We used absolute and relative frequencies to describe categorical data and means with standard deviations or medians with IQR and ranges to describe numerical data. Comparisons between hepatitis A and hepatitis E groups were performed using both univariate methods (t-test for continuous variables with normal distribution according to the Shapiro-Wilk test, Mann-Whitney test for continuous variables with non-normal distribution, Fisher test for binary variables) as well as two multivariate logistic regression models adjusting for 1: age & gender and 2: all variables taken into account. Prior to logistic models, right-skewed data were transformed using the base 10 logarithm. All statistical tests used a significance cut-off of p<0.05.

# Results

A total of 48 hepatitis E adult patients and 152 hepatitis A adult patients were included. No pregnant women were found in either group. No hepatitis E cases were registered in pediatric patients. Hepatitis E cases represented 9.62% from all registered cases of acute viral hepatitis during the study period, including legal minors (Figure 1). All hepatitis E cases are believed to be autochthonous but precise food-borne sources could not be reliably assessed.




Figure 1. Distribution of acute viral hepatitis cases during the study period (2017 Jan 1 to 2019 Aug 30).

Most cases in both groups were male (M/F ratio: 1.47) and hepatitis E patients were significantly older than hepatitis A patients (Table 1).

Patients in both groups had statistically similar median hospitalization length. The maximum duration was 43 days in a hepatitis E patient and 38 days in a hepatitis A patient (Table 1).

Hepatitis E patients had significantly milder abnormalities in laboratory values at presentation for direct & total bilirubin, AST, ALT, ALP, INR and prothrombin index and γ-GT (if adjusted for age & gender) (Table 1, Figure 2).

Table 1. Hospitalization and laboratory parameters of the hepatitis E and A groups.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Hepatitis (Group)** | | **E**  **n (%)** | **A**  **n (%)** | **Univariate statistics** | **Adjusted OR1**  **p, [95% CI]** |
| **48 (24.0)** | **152 (76.0)** |  |  |
| Gender | M | 31 (64.6) | 88 (57.9) | ns. |  |
| F | 17 (35.4) | 64 (42.1) |  |  |
| Age at presentation  (years) | μ ±DS | 50.62 ±15.6 | 39.06 ±15.0 | MW: p<.001 |  |
| 50+ | 28 (58.3) | 31 (20.4) |  |  |
| [40,50) | 7 (14.6) | 28 (18.4) |  |  |
| [30,40) | 7 (14.6) | 52 (34.2) |  |  |
| [18,30) | 6 (12.5) | 41 (27.0) |  |  |
| Hospital stay duration (days) | Med (IQR) | 9 (7-14) | 11 (8-14) | MW: ns. | ns. |
| Direct bilirubin (mg/dL) | Med (IQR) | 1.24  (0.34-5.02) | 4.9  (2.66-6.99) | MW: p<.001 | 0.194, p<.001,  [0.09, 0.38] \* |
| Total bilirubin (mg/dL) | Med (IQR) | 1.73  (0.68-5.76) | 5.87  (3.38-8.2) | MW: p<.001 | 0.182, p<.001,  [0.08, 0.39] \* |
| ALP (IU/L) | Med (IQR) | 154.5  (119.25-192.75) | 205  (159.25-260.5) | MW: p<.001 | 0.046, p=.003  [0.01, 0.34] \* |
| γ-GT (IU/L) | Med (IQR) | 229  (123.5-327) | 246  (154.75-355.5) | MW: ns. | 0.343, p<.048,  [0.12, 0.99] \* |
| AST (IU/L) | Med (IQR) | 145.5  (69-676.75) | 870  (304.5-1666.75) | MW: p<.001 | 0.112, p<.001,  [0.05, 0.23] \* |
|  | > 350 | 17 (35.4) | 99 (65.1) | OR=0.29, p<.001,  [0.15, 0.58] | 0.249, p<.001,  [0.12, 0.51] |
| ALT (IU/L) | Med (IQR) | 401  (122.75-886.25) | 1817.5  (919.25-2801.75) | MW: p<0.001 | 0.045, p<.001,  [0.02, 0.11] \* |
|  | > 350 | 26  (54.2) | 132  (86.8) | OR=0.18, p<.001,  [0.09, 0.37] | 0.12, p<.001,  [0.05, 0.27] |
| Prothrombin index (%) | Med (IQR) | 88.25  (75.2-100.38) | 72.7  (59.9-86.85) | T-test: p<0.001 | 1.039, p<.001,  [1.02, 1.06] |
|  | < 70 | 9 (18.8) | 60 (42.0) | OR=0.32, p=.005,  [0.14, 0.71] | 0.268, p=.002,  [0.11, 0.61] |
| INR | Med (IQR) | 1.06  (0.99-1.13) | 1.16  (1.07-1.31) | MW: p<.001 | 0.036, p=.002,  [0.0, 0.26] |
| > 1.5 | 4 (8.3) | 16 (11.2) | ns. | ns. |
| 1: odds-ratio adjusted on age and gender; \*: marked variables were transformed to base 10 logarithm prior to logistic regression due to skewness, therefore odds-ratios show tenfold increases/decreases in the respective laboratory parameters; μ ±SD: mean ±1 standard deviation; Med (IQR): median (inter-quartile range); MW: Mann-Whitney test; OR: odds-ratio with p-value and 95% confidence interval; ns.: not statistically significant at ɑ=0.05; ALP: Alkaline Phosphatase; γ-GT: Gamma-glutaryl Transferase; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase. | | | | | |




Figure 2. Several patient parameters differed significantly between hepatitis A and E groups. Laboratory reference ranges have been marked by horizontal red lines. Means are marked by diamonds. P-values from univariate Mann-Whitney tests

Table 2 summarizes chronic conditions ~~significantly~~ associated with hepatitis E compared to hepatitis A: chronic liver disease, chronic kidney disease, neurologic disease, diabetes mellitus (univariate and adjusted for age & gender and other comorbidities).

Significantly more hepatitis E patients needed additional treatment (ribavirin) than hepatitis A patients (plasma) with OR=6.8 (OR=4.9 adjusted for age & gender) (Table 2). All hepatitis E patients who received ribavirin had favorable evolution and were either discharged at home or to another department for specialized treatment of their comorbidities (Table 3).

The three deceased patients (6.25% of all hepatitis E patients and 23.1% of hepatitis E patients with preexisting liver disease) had hepatitis E infection superimposed on end-stage alcoholic liver disease. Two of them died because of bleeding from esophageal varices. The third patient, with chronic hepatitis B infection and *Streptococcus tholarensis* endocarditis, died because of cerebral hemorrhage, septic cerebral embolism and multiple systemic organ failure (Table 4).

Table 2. Preexisting conditions and severity factors for hepatitis E and A patients.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Hepatitis (Group)** | **E**  **n (%)** | **A**  **n (%)** | **OR (univariate)**  **p, [95% CI]** | **Adjusted OR (univariate)1**  **p, [95% CI]** | **OR (multivariate)2**  **p, [95% CI]** |
| Chronic liver disease | 13  (27.1) | 6  (3.9) | 9.04], p<.001  [3.21, 25.45 | 7.19, p<.001  [2.53, 22.73] | 6.21, p=.002  [2.0, 20.5] |
| *Liver cirrhosis* | *6*  *(12.5)* | *1*  *(0.7)* | *21.57*, *p<.001*  *[2.53, 184.16]* | *12.5, p=.026*  *[1.86, 250]* |
| *Hepatitis B coinfection* | *6*  *(12.5)* | *4*  *(2.6)* | *5.29*, *p=.014*  *[1.43, 19.60]* | *6.71, p=.007*  *[1.7, 29.41]* |
| Neurologic disease | 6  (12.5) | 2  (1.3) | 10.71, p=.003  [2.09, 55.04] | 9.52, p=.011  [1.89, 71.43] | 4.76, p=.098  [0.8, 38.3] |
| Chronic kidney disease | 5  (10.4) | 2  (1.3) | 8.72, p=.009  [1.63, 46.54] | 5.18, p=.065  [0.99, 38.46] | 6.175, p=.056)  [0.99, 50.0] |
| Diabetes mellitus | 10  (20.8) | 9  (5.9) | 4.18, p=.004  [1.59, 11.02] | 2.04, p=.190  [0.69, 5.99] | 3.39, p=.029  [1.1, 10.1] |
| Additional treatment\* | 9  (18.8) | 5  (3.3) | 6.78, p=.001  [2.15, 21.40] | 4.93, p=.010  [1.49, 17.86] | 4.47, p=.025  [1.2, 17.25] |
| 1: odds-ratio adjusted for age and gender; 2: odds-ratio in multiple logistic regression with all listed covariates (liver cirrhosis and hepatitis B coinfection included under chronic liver disease); \* Additional treatment: hepatitis E – ribavirin, hepatitis A – plasma products. | | | | | |

Table 3. Hepatitis E patients who received ribavirin treatment. Summary of laboratory values (at admission / at discharge or transfer) and preexistent conditions

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Age** | **Sex** | **Direct bilirubin (mg/dL)** | **AST (IU/L)** | **ALT (IU/L)** | **INR** | **Recommendation for ribavirin treatment according to EASL guidelines** | **Evolution** | **MELD score**  **(3-months risk of death)** |
| 51 | F | 28.51 / 21.51 | 36 / 59 | 15 / 24 | 1.17 / 1.02 | Breast cancer, liver, lung and bone metastases | Transfer to gastroenterology dept. |  |
| 21 | M | 0.25 / 0.19 | 19 / 20 | 75 / 35 | 0.92 / 0.99 | Sagittal sinus thrombosis, bilateral facial palsy, one episode of seizures | Transfer to neurology dept. |  |
| 36 | M | 25.02 / 19.17 | 191 / 149 | 322 / 214 | 1.27 / 1.41 | Chronic hepatitis B with advanced fibrosis | Transfer to gastroenterology dept. | 23 (19.6%) |
| 38 | M | 1.67 / 1.98 | 1010 / 147 | 1750 / 607 | 1.12 / 1.02 | Hodgkin lymphoma with chemotherapy, bone marrow transplantation | Discharged at home. |  |
| 63 | M | 16.64 / 3.9 | 270 / 53 | 865 / 80 | 1.34 / 1.36 | Coagulation deficiency factors VIII & IX, autoimmune hepatitis | Discharged at home |  |
| 64 | M | 0.27 / 0.32 | 321 / 74 | 1014 / 332 | 0.99 / 0.96 | Retroperitoneal liposarcoma | Discharged at home |  |
| 69 | M | 1.31 / 0.81 | 570 / 85 | 436 / 141 | 1.12 / 1.01 | Newly diagnosed colon cancer, diabetes mellitus | Discharged at home |  |
| 74 | M | 0.67 / 1.16 | 460 / 37 | 1013 / 219 | 1.06 / 0.96 | Ethanolic liver cirrhosis, Alzheimer and vascular and dementia, diabetes mellitus | Discharged at home | 7 (1.9%) |
| 75 | M | 24.1 / 7.11 | 645 / 44 | 374 / 23 | 1.57 / 1.38 | Newly diagnosed ethanolic liver cirrhosis and hepatocarcinoma | Transfer to gastroenterology dept. | 24 (19.6%) |

Table 4. Summary of laboratory values (at admission / last before death) and preexisting conditions in patients who died with acute hepatitis E.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Age** | **Sex** | **Direct bilirubin (mg/dL)** | **AST (IU/L)** | **ALT (IU/L)** | **INR** | **Preexisting conditions interpreted as causes of death** | **MELD score**  **(3-months risk of death)** |
| 59 | M | 18.99 / 28.3 | 618 / 73 | 262 / 16.6 | 1.8 / 4.15 | Hemorrhagic shock from esophageal varices, alcoholic liver cirrhosis (Child-Pugh C) | 35 (52.6%) |
| 61 | M | 12.8 / 23.71 | 1537 / 253 | 526 / 39.9 | 1.8 / 1.81 | Hemorrhagic shock from esophageal varices, alcoholic liver cirrhosis (Child-Pugh C) | 27 (19.6%) |
| 65 | M | 4.92 / 14.51 | 157 / 23 | 50 / 56.4 | 1.54 / 1.37 | Multiple system organ failure, alcoholic and hepatitis B viral cirrhosis (Child-Pugh B), endocarditis, cerebral embolism | 31 (52.6%) |

Highly elevated MELD scores were found in severe cases of HE with acute-on-chronic liver failure, including the three deceased patients (Tables 3-4).

# Discussion

Our study showed not only an increased incidence of hepatitis E in recent years but also an unexpectedly high number of severe and / or lethal cases as an emerging source of morbidity and health care costs. This increase cannot be explained by better detection as the same protocol was used since 2016. Indeed, other European countries have experienced a similar pattern with no definitive explanation. In several countries, hepatitis E may become the most frequent cause of acute viral hepatitis [3, 26]. In 2018, in our hospital, a great number of hepatitis A cases were admitted, mainly in children and young adults.

The diagnosis and follow-up of hepatitis E include serological and PCR-based genotyping assays [5, 27]. In our patients, diagnosis was based on clinical criteria (suspicion of acute viral hepatitis or elevated liver enzymes) and serological testing, ready within 1-2 days. All new acute cases were tested for viral hepatitis A-E on the same laboratory request according to the hospital protocol.

According to HEV seroprevalence studies, no gender difference was found, but acute infection has a higher incidence in men, similar to our study [7, 28]. No definitive explanation has been provided but behavioral factors, food preference and comorbidities (such as alcoholism and chronic liver disease, more prevalent in men [29, 30]) may have contributed to it.

In our sample, hepatitis E affected only adults, with a median age of 52, similar to acute hepatitis B and C [29, 31, 32], while hepatitis A is found mainly in children and young adults [29, 31]. This imbalance may be attributed to both preexisting liver conditions as well as alimentary habits.

Since low infecting doses tend to cause only asymptomatic infection [5, 33] clinical manifestations may be associated with either larger meals or highly contaminated food items.

Preexisting conditions are associated with clinical manifestations of hepatitis E. Acute hepatitis E may develop as acute-on-chronic liver disease with high fatality rates [15]. Diabetes mellitus may slow-down liver regeneration and may cause considerable immunosuppression [34]. We found more chronic conditions in hepatitis E patients compared to hepatitis A which may explain the higher prevalence of severe clinical courses and a higher fatality of hepatitis E irrespective of age and gender.

Generally, hepatitis E is mild enough needing only supportive treatment. Severe, immunocompromised patients and patients with acute-on-chronic liver disease are candidates for etiologic treatment with ribavirin and PEGylated interferon-alpha, with expected favorable results [5, 35].

Among the 9 patients who received ribavirin, significant improvement was found in all cases; patients were either discharged at home or transferred to other departments for further care of their comorbidities. Acute-on-chronic liver failure was demonstrated in 3 of the treated cases, 5 other cases had immunologic deficiencies and another one presented with neurologic manifestations that triggered the search for hepatitis E infection.

The 3 deceased patients with acute-on-chronic end-stage liver disease with fulminant evolution and/or severe comorbidities did not receive etiologic treatment because of severe thrombocytopenia.

Only 5 (3.3%) hepatitis A cases developed severe disease with coagulation abnormalities and received plasma products, all with favorable outcome. Overall, more hepatitis E cases required additional treatment compared to hepatitis A despite apparent milder disease.

Our study had several limitations: Genotyping was not possible, we presumed that genotypes 3 and 4 are found in Romania, as elsewhere in Europe [5]. No reliable data on our patient’s alimentary habits was available but the assumption is that pork products are responsible for most cases in a similar manner to other European countries [7]. Follow-up was not insured in all cases, which may have been valuable in measuring the rate of chronic HEV infection.

# Conclusions

An increased number of hepatitis E cases were admitted to our institution in the last two years. Hepatitis E was generally milder than hepatitis A, more frequently found in older patients with preexisting conditions. Ribavirin treatment seems to be beneficial in patients with acute-on-chronic liver disease and immunosuppression.

# References

1. Purdy MA, Harrison TJ, Jameel S, Meng X-J, Okamoto H, Van der Poel WHM, Smith DB, ICTV Report Consortium (2017) ICTV Virus Taxonomy Profile: Hepeviridae. J Gen Virol 98:2645–2646

2. Smith DB, Simmonds P, members of the International Committee on the Taxonomy of Viruses Hepeviridae Study Group, Jameel S, Emerson SU, Harrison TJ, Meng X-J, Okamoto H, Van der Poel WHM, Purdy MA (2014) Consensus proposals for classification of the family Hepeviridae. J Gen Virol 95:2223–2232

3. Adlhoch C, Avellon A, Baylis SA, et al (2016) Hepatitis E virus: Assessment of the epidemiological situation in humans in Europe, 2014/15. J Clin Virol 82:9–16

4. Bouwknegt M, Frankena K, Rutjes SA, Wellenberg GJ, de Roda Husman AM, van der Poel WHM, de Jong MCM (2008) Estimation of hepatitis E virus transmission among pigs due to contact-exposure. Vet Res 39:40

5. Dalton HR, Kamar N, Baylis SA, Moradpour D, Wedemeyer H, Negro F (2018) EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol 68:1256–1271

6. Rutjes SA, Lodder WJ, Lodder-Verschoor F, van den Berg HHJL, Vennema H, Duizer E, Koopmans M, Husman AM de R (2009) Sources of Hepatitis E Virus Genotype 3 in the Netherlands. Emerg Infect Dis 15:381–387

7. Faber M, Askar M, Stark K (2018) Case-control study on risk factors for acute hepatitis E in Germany, 2012 to 2014. Eurosurveillance. doi: 10.2807/1560-7917.ES.2018.23.19.17-00469

8. Renou C, Roque-Afonso A-M, Pavio N (2014) Foodborne Transmission of Hepatitis E Virus from Raw Pork Liver Sausage, France. Emerg Infect Dis 20:1945–1947

9. Said B, Ijaz S, Kafatos G, Booth L, Thomas HL, Walsh A, Ramsay M, Morgan D, on behalf of the Hepatitis E Incident Investigation Team (2009) Hepatitis E Outbreak on Cruise Ship. Emerg Infect Dis 15:1738–1744

10. Boxall E, Herborn A, Kochethu G, Pratt G, Adams D, Ijaz S, Teo C-G (2006) Transfusion-transmitted hepatitis E in a “nonhyperendemic” country. Transfus Med 16:79–83

11. Matsubayashi K, Kang J-H, Sakata H, et al (2008) A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion (Paris) 48:1368–1375

12. Galiana C, Fernández-Barredo S, García A, Gómez MT, Pérez-Gracia MT Short Report: Occupational Exposure to Hepatitis E Virus (HEV) in Swine Workers. 4

13. Loyon L (2018) Overview of Animal Manure Management for Beef, Pig, and Poultry Farms in France. Front Sustain Food Syst 2:36

14. Kamar N, Garrouste C, Haagsma EB, et al (2011) Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants. Gastroenterology 140:1481–1489

15. Zhang S, Chen C, Peng J, et al (2017) Investigation of underlying comorbidities as risk factors for symptomatic human hepatitis E virus infection. Aliment Pharmacol Ther 45:701–713

16. Debing Y, Moradpour D, Neyts J, Gouttenoire J (2016) Update on hepatitis E virology: Implications for clinical practice. J Hepatol 65:200–212

17. Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, Van der Eijk AA (2017) Hepatitis E virus: Infection beyond the liver? J Hepatol 66:1082–1095

18. Dalton HR, Stableforth W, Thurairajah P, et al (2008) Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease: Eur J Gastroenterol Hepatol 20:784–790

19. Goyal R, Kumar A, Panda SK, Paul SB, Acharya SK (2012) Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: a preliminary report. Antivir Ther 17:1091–1096

20. Péron JM, Dalton H, Izopet J, Kamar N (2011) Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: A role for ribavirin? J Hepatol 54:1323–1324

21. Dalton HR, Kamar N, van Eijk JJJ, Mclean BN, Cintas P, Bendall RP, Jacobs BC (2016) Hepatitis E virus and neurological injury. Nat Rev Neurol 12:77–85

22. Jha AK, Nijhawan S, Nepalia S, Suchismita A (2012) Association of Bell’s Palsy with Hepatitis E Virus Infection: A Rare Entity. J Clin Exp Hepatol 2:88–90

23. Gérolami R, Moal V, Colson P (2008) Chronic Hepatitis E with Cirrhosis in a Kidney-Transplant Recipient. N Engl J Med 358:859–860

24. Legrand‐Abravanel F, Kamar N, Sandres‐Saune K, Garrouste C, Dubois M, Mansuy J, Muscari F, Sallusto F, Rostaing L, Izopet J (2010) Characteristics of Autochthonous Hepatitis E Virus Infection in Solid‐Organ Transplant Recipients in France. J Infect Dis 202:835–844

25. VIDAS® Hepatitis panel. In: BioMérieux Clin. Diagn. Routine and confirmation testing of Hepatitis A, B, C and E. Accessed 22 Sep 2019

26. Doting MHE, Weel J, Niesters HGM, Riezebos-Brilman A, Brandenburg A (2017) The added value of hepatitis E diagnostics in determining causes of hepatitis in routine diagnostic settings in the Netherlands. Clin Microbiol Infect 23:667–671

27. Vollmer T, Diekmann J, Eberhardt M, Knabbe C, Dreier J (2016) Monitoring of Anti-Hepatitis E Virus Antibody Seroconversion in Asymptomatically Infected Blood Donors: Systematic Comparison of Nine Commercial Anti-HEV IgM and IgG Assays. Viruses 8:232

28. Faber MS, Wenzel JJ, Jilg W, Thamm M, Höhle M, Stark K (2012) Hepatitis E Virus Seroprevalence among Adults, Germany. Emerg Infect Dis 18:1654–1657

29. (2017) Analiza evoluției bolilor transmisibile aflate în supraveghere, Raport pentru anul 2016.

30. Flemming JA, Dewit Y, Mah JM, Saperia J, Groome PA, Booth CM (2019) Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. Lancet Gastroenterol Hepatol 4:217–226

31. Drositis I, Bertsias A, Lionis C, Kouroumalis E (2013) Epidemiology and molecular analysis of hepatitis A, B and C in a semi-urban and rural area of Crete. Eur J Intern Med 24:839–845

32. Hofstraat S, Falla A, Veldhuijzen I, Hahné S, Benthem BHB van, Tavoschi L, Europäisches Zentrum für die Prävention und die Kontrolle von Krankheiten (2016) Systematic review on hepatitis B and C prevalence in the EU/EEA.

33. Hewitt PE, Ijaz S, Brailsford SR, et al (2014) Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. The Lancet 384:1766–1773

34. Singh KK, Panda SK, Shalimar, Acharya SK (2013) Patients with Diabetes Mellitus are Prone to Develop Severe Hepatitis and Liver Failure due to Hepatitis Virus Infection. J Clin Exp Hepatol 3:275–280

35. Kamar N, Pischke S (2019) Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment. Cold Spring Harb Perspect Med 9:a031872

1. R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/. [↑](#footnote-ref-1)